Literature DB >> 10751925

Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.

E C Etchebehere1, M C Lima, W Passos, J A Maciel Júnior, A O Santos, C D Ramos, E E Camargo.   

Abstract

Olanzapine, an atypical antipsychotic drug, was administered to a patient with Huntington's disease (HD) with marked choreiform movements. Brain SPECT with 99mTc-HMPAO was performed before and after treatment. Brain SPECT imaging has been performed in patients with HD in order to determine the status of basal ganglia perfusion. The use of brain SPECT with 99mTc-HMPAO before and after treatment in patients with HD has not been yet reported. The marked hypoperfusion of the basal ganglia on brain SPECT performed before therapy with olanzapine improved significantly after treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10751925     DOI: 10.1590/s0004-282x1999000500021

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 3.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.